Parkinson's Disease and alpha-Synuclein Expression

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Movement Disorders

• Publication date

  2011-10-01

• Fields of study

  Biology, Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Beta2-Adrenergic Suppression of Neuroinflammation in Treatment of Parkinsonism, with Relevance for Neurodegenerative and Neoplastic Disorders

  2024cites this paper
• Role of Deubiquitinases in Parkinson’s Disease—Therapeutic Perspectives

  2023cites this paper
• Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model

  2023cites this paper
• A Mouse Model to Test Novel Therapeutics for Parkinson’s Disease: an Update on the Thy1-aSyn (“line 61”) Mice

  2023cites this paper
• The Significance of NLRP Inflammasome in Neuropsychiatric Disorders

  2022cites this paper
• Potential therapeutic use of plant flavonoids in AD and PD

  2022cites this paper
• Ghrelin alleviates 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells

  2021cites this paper
• A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data

  2021cites this paper
• A Phase II study to evaluate the safety and efficacy of prasinezumab in early 1 Parkinson's disease (PASADENA): rationale, design and baseline data 2

  2021cites this paper
• Auditory Dysfunction in Parkinson's Disease

  2020cites this paper
• S-Nitrosylation of G protein-coupled receptor kinase 6 and Casein kinase 2 alpha modulates their kinase activity toward alpha-synuclein phosphorylation in an animal model of Parkinson’s disease

  2020cites this paper
• Network Analysis and Human Single Cell Brain Transcriptomics Reveal Novel Aspects of Alpha-Synuclein (SNCA) Biology

  2020cites this paper
• Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

  2019cites this paper
• Alpha-synuclein as therapeutic target in Parkinson’s disease

  2019cites this paper
• Cellular models of alpha‐synuclein toxicity and aggregation

  2019cites this paper
• CCAAT/enhancer binding protein δ is a transcriptional repressor of α-synuclein

  2019cites this paper
• CRISPR System: A High-throughput Toolbox for Research and Treatment of Parkinson’s Disease

  2019cites this paper
• Alpha‐synuclein aggregates activate calcium pump SERCA leading to calcium dysregulation

  2018cites this paper
• Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson’s disease

  2018cites this paper
• Cardiolipin exposure on the outer mitochondrial membrane modulates α-synuclein

  2018cites this paper
• A single cell high content assay detects mitochondrial dysfunction in iPSC-derived neurons with mutations in SNCA

  2018cites this paper
• A Druggable Genome Screen Identifies Modifiers of α-Synuclein Levels via a Tiered Cross-Species Validation Approach

  2018cites this paper
• The Molecular Mechanism of Alpha-Synuclein Dependent Regulation of Protein Phosphatase 2A Activity

  2018cites this paper
• A new hypothesis for Parkinson’s disease pathogenesis: GTPase-p38 MAPK signaling and autophagy as convergence points of etiology and genomics

  2018cites this paper
• The Identification of Alpha-Synuclein as the First Parkinson Disease Gene

  2017cites this paper
• The Yin and Yang of nucleic acid‐based therapy in the brain

  2017cites this paper
• Research Highlights : We introduce a new concept , the systemic chemogenomics / QSAR

  2017cites this paper
• miR-135b Plays a Neuroprotective Role by Targeting GSK3β in MPP+-Intoxicated SH-SY5Y Cells

  2017cites this paper
• Systemic QSAR and phenotypic virtual screening: chasing butterflies in drug discovery.

  2017cites this paper
• Association between SNCA rs2736990 polymorphism and Parkinson's disease: a meta-analysis.

  2017cites this paper
• Dysregulated microRNAs in neural system: Implication in pathogenesis and biomarker development in Parkinson's disease.

  2017cites this paper
• The role of α-synuclein in the pathology of murine mucopolysaccharidosis type IIIA

  2017cites this paper
• LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives

  2016influential citation
• Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.

  2016cites this paper
• MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson’s disease

  2016cites this paper
• Retrograde Axonal Degeneration in Parkinson Disease

  2016cites this paper
• Neuropathology of α‐synuclein propagation and braak hypothesis

  2016influential citation
• Parkinson's disease: acid‐glucocerebrosidase activity and alpha‐synuclein clearance

  2016cites this paper
• Structural Properties of α-Synuclein in Functional and Pathological Contexts

  2016cites this paper
• Finding the ‘Guilty’ Gene Variant of Sporadic Parkinson’s Disease Via CRISPR/Cas9

  2016cites this paper
• Endolysosomal Dysfunction in Parkinson Disease: The Role of Disease Mutations in ATP13A2 and LRRK2.

  2016cites this paper
• Glucocerebrosidase Deficiency in Drosophila Results in α-Synuclein-Independent Protein Aggregation and Neurodegeneration

  2016cites this paper
• Sporadic inclusion-body myositis: A degenerative muscle disease associated with aging, impaired muscle protein homeostasis and abnormal mitophagy.

  2015cites this paper
• Les oligodendrocytes sont-ils concernés par l'accumulation d'alpha-synucleine pathologique dans le cerveau de souris TGM83 : études immunohistochimiques comparées

  2015cites this paper
• Proteomics in neurodegenerative diseases: Methods for obtaining a closer look at the neuronal proteome

  2015cites this paper
• Link between the SNCA gene and parkinsonism.

  2015cites this paper
• Parkinson's disease

  2015cites this paper
• α-Synuclein Over-Expression Induces Increased Iron Accumulation and Redistribution in Iron-Exposed Neurons

  2015cites this paper
• Neuropathology of Parkinson’s Disease

  2014cites this paper
• Development of targeted therapies for Parkinson’s disease and related synucleinopathies

  2014cites this paper
• Tetranectin Knockout Mice Develop Features of Parkinson Disease

  2014cites this paper
• Identification of a novel Parkinson’s disease locus via stratified genome-wide association study

  2014cites this paper
• LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance

  2014cites this paper
• Synucleins Regulate the Kinetics of Synaptic Vesicle Endocytosis

  2014cites this paper
• Zn²⁺ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation.

  2014cites this paper
• Protective effect of alpha-synuclein knockdown on methamphetamine-induced neurotoxicity in dopaminergic neurons

  2014cites this paper
• Interactions between cell adhesion and the synaptic vesicle cycle in Parkinson's disease.

  2014cites this paper
• Regulation of Alpha Synuclein Following Chronic Methamphetamine Administration in Guinea Pigs: Correlation with Memory and Synaptic Plasticity

  2013cites this paper
• Linking the structure of alpha-synuclein oligmers to function in Parkinson's disease

  2013cites this paper
• A novel α-synuclein-GFP mouse model displays progressive motor impairment, olfactory dysfunction and accumulation of α-synuclein-GFP.

  2013cites this paper
• The many faces of alpha‐synuclein mutations

  2013cites this paper
• RNA interference targeting α-synuclein attenuates methamphetamine-induced neurotoxicity in SH-SY5Y cells.

  2013cites this paper
• Brain Activation of SIRT1: Role in Neuropathology

  2013cites this paper
• Mitochondrial quality, dynamics and functional capacity in Parkinson’s disease cybrid cell lines selected for Lewy body expression

  2013cites this paper
• Pale Body-Like Inclusion Formation and Neurodegeneration following Depletion of 26S Proteasomes in Mouse Brain Neurones are Independent of α-Synuclein

  2013cites this paper
• α-Synuclein as a ferrireductase.

  2013cites this paper
• Multiple System Atrophy and Parkinson ’ s disease

  2013cites this paper
• Native α-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2

  2013cites this paper
• Long‐term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease

  2013cites this paper
• Alpha‐synuclein gene duplication: Marked intrafamilial variability in two novel pedigrees

  2013cites this paper
• Increased Neuronal α-Synuclein Pathology Associates with Its Accumulation in Oligodendrocytes in Mice Modeling α-Synucleinopathies

  2012cites this paper
• An apple a day to prevent Parkinson disease

  2012cites this paper
• by flavonoids An apple a day to prevent Parkinson disease : Reduction of risk

  2012cites this paper
• Pathogenic Considerations in Sporadic Inclusion-Body Myositis, a Degenerative Muscle Disease Associated With Aging and Abnormalities of Myoproteostasis

  2012cites this paper
• Mickael Decressac in Nigral Dopamine Neurons Induced Down-Regulation of Nurr 1 Disrupts GDNF Signaling −-Synuclein

  2012cites this paper
• The Role of Alpha-Synuclein Oligomerization and Aggregation in Cellular and Animal Models of Parkinson’s Disease

  2012cites this paper
• Aggregation of αSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons

  2011cites this paper
• Clinical Pharmacology: Advances and Applications Dovepress

  year unknowncites this paper